Back to top
more

Genomic Health, Inc. (GHDX)

(Delayed Data from NSDQ)

$67.55 USD

67.55
321,603

+1.67 (2.53%)

Updated May 3, 2019 04:00 PM ET

After-Market: $67.63 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Medtronic (MDT) Rides on Innovation, Rising Costs a Woe

by Zacks Equity Research

Medtronic (MDT) continues to meaningfully accelerate all its three fundamental growth strategies, namely therapy innovation, globalization and economic value.

    Walgreens Boots (WBA) Grows on New Pacts Amid Several Woes

    by Zacks Equity Research

    Walgreens Boots' (WBA) alliance with Express Scripts is expected to expand both companies' existing group purchasing efforts.

      Boston Scientific to Buy Cryterion Medical to Widen EP Suite

      by Zacks Equity Research

      Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.

        Here's Why You Should Add Bio-Rad (BIO) to Your Portfolio

        by Zacks Equity Research

        We are upbeat about Bio-Rad's (BIO) solid growth in geographies like North America, China and Asia Pacific.

          Arbutus Biopharma (ABUS) Jumps: Stock Rises 9.6%

          by Zacks Equity Research

          Arbutus Biopharma (ABUS) was a big mover last session, as the company saw its shares rise more than 9% on the day, amid huge volumes.

            Insulet Omnipod Insulin Pump Finds Favor in British Columbia

            by Zacks Equity Research

            Insulet's (PODD) Omnipod has huge market potential in Canada as it is the only tubeless insulin pump sold in the region.

              Here's Why You Should Invest in Masimo (MASI) Right Now

              by Zacks Equity Research

              Masimo's (MASI) raised guidance for 2018 and strong fundamentals make it a lucrative pick.

                Insulet Starts European Direct Operation, Braces Global Base

                by Zacks Equity Research

                Insulet's (PODD) goal to begin direct commercial operation in Europe is a year-long endeavor.

                  Henry Schein's JV With Internet Brands to Boost Dental Arm

                  by Zacks Equity Research

                  Henry Schein (HSIC) and Internet Brands' newly formed JV is likely to deliver integrated dental technology for improving practice management, marketing as well as patient communication.

                    Integer Holdings Offloads AS&O, Focuses on Cardiac Units

                    by Zacks Equity Research

                    Integer Holdings (ITGR) divests core AS&O unit to MedPlast, LLC for $600 million; aims to focus on cardiac business.

                      Insulet Banks on Omnipod's Growing Market Reach, Runs Risks

                      by Zacks Equity Research

                      We are upbeat about the solid uptake of Insulet's (PODD) Omnipod System in the United States and other geographies.

                        Brush Off Volatility Concerns With These 5 Low-Beta Stocks

                        by Zacks Equity Research

                        We create a strategy that singles out less-risky stocks which can generate impressive returns only when certain parameters are considered.

                          Here's Why You Should Hold Wright Medical (WMGI) Stock Now

                          by Zacks Equity Research

                          Here we take a quick look at the major factors that have been plaguing Wright Medical and discuss the prospects that ensure near-term recovery.

                            Here's Why You Should Invest in Align Technology (ALGN) Now

                            by Zacks Equity Research

                            We are upbeat about Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally, particularly in the Asia-Pacific and EMEA regions.

                              Stryker or Baxter: Which is a Better Pick for Your Portfolio?

                              by Zacks Equity Research

                              Stryker (SYK) and Baxter's (BAX) strong expected growth rates and rising share price make them close contenders in the MedTech industry.

                                Pfizer's Leukemia Candidate Gets Priority Review From FDA

                                by Zacks Equity Research

                                The FDA grants a priority review to Pfizer's (PFE) NDA for leukemia candidate glasdegib for the first-line treatment of acute myeloid leukemia (AML) in combination with chemotherapy.

                                  Here's Why You Should Add Abaxis (ABAX) to Your Portfolio

                                  by Zacks Equity Research

                                  We are upbeat about Abaxis' (ABAX) solid consumable and instrument sales growth along with strength in the medical and veterinary market segments.

                                    Here's Why You Should Hold Varian Medical (VAR) Stock Now

                                    by Zacks Equity Research

                                    Here we analyze the major factors that have been plaguing Varian Medical (VAR) and discuss the prospects that ensure near-term recovery.

                                      Thermo Fisher to Buy Gatan, Boost Electron Microscopy Suite

                                      by Zacks Equity Research

                                      Thermo Fisher (TMO) forges ahead with initiatives to strengthen foothold in the high-potential electron microscopy market.

                                        MOHAP Selects Masimo's (MASI) Eve for CCHD Screening in UAE

                                        by Zacks Equity Research

                                        Masimo's (MASI) Eve with Rad-97 Pulse CO-Oximeter to be integrated in nine hospitals across UAE for CCHD screening in newborns.

                                          McKesson (MCK) Issues Strong Preliminary Results for Q1

                                          by Zacks Equity Research

                                          McKesson Corporation (MCK) declares solid preliminary results for Q1, courtesy of deals, divestitures and acquisitions.

                                            Walgreens (WBA) Tops Q3 Earnings Estimates, Narrows View

                                            by Zacks Equity Research

                                            Walgreens Boots (WBA) is upbeat about the recent acquisition of stores from Rite Aid which has already started to strengthen its U.S. pharmacies business.

                                              Stryker (SYK) to Acquire SafeAir, Reduce Surgical Smoke

                                              by Zacks Equity Research

                                              The acquisition of SafeAir likely to boost Stryker's (SYK) core MedSurg and Neurotechnology segments.

                                                Here's Why You Should Steer Clear of Fresenius Medical Now

                                                by Zacks Equity Research

                                                Soft segmental performance and a downbeat revenue guidance reflect Fresenius Medical's (FMS) weaknesses.

                                                  Agios Out-Licenses China Rights to Leukemia Drug Tibsovo

                                                  by Zacks Equity Research

                                                  Agios (AGIO) and CStone Pharmaceticals sign an exclusive collaboration and license agreement for the development and commercialization of its lead pipeline candidate Tibsovo.